ClinicalTrials.gg
CompletedNCT05022771Updated Jan 31, 2023

A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of PMG1015

A Phase 1 interventional study of PMG1015 Dose 1 and PMG1015 Dose 2 in Idiopathic Pulmonary Fibrosis, sponsored by Pulmongene Ltd.. Completed at 1 site in Australia. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-31.

Sponsored by Pulmongene Ltd. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Idiopathic Pulmonary Fibrosis with a site in Australia — 11 open to participants now, 16 under way, 4 of them phase 3. Idiopathic Pulmonary Fibrosis · Australia.

Enrollment
54th of 64
54 · median 165
Started
2021
with 3 others
Phase 1
10 of 64
3 open now
Registered
31st of 64
by date

Among the 64 studies in Idiopathic Pulmonary Fibrosis with a site in Australia, this one is the 54th largest by enrollment, is one of 4 that started in 2021, is one of 10 in phase 1, and was the 31st registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 122 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

11 of the 64 studies in Idiopathic Pulmonary Fibrosis with a site in Australia are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 84 Idiopathic Pulmonary Fibrosis studies recruiting now, 55 (65%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Idiopathic Pulmonary Fibrosis with a site in Australia, or all of them as a file.
02

Study summary

This is a Phase 1A, first in human, randomized, double-blinded, placebo-controlled, dose escalation study of PMG1015 in healthy adult volunteers. PMG1015 is a monoclonal antibody, being developed as a novel therapeutic treatment for patients with Idiopathic Pulmonary fibrosis (IPF). This study aims to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PMG1015 after Single ascending doses (SAD).

Read the detailed description

Participants will be enrolled and randomized into 1 of 7 cohorts in a double-blind manner.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male or non-pregnant, non-lactating female volunteers, between 18 and 60 years of age, inclusive at the time of .
  2. (BMI) between 17.5 and 32.0 kg/m2 (inclusive) and body weight between 50 and 100 kg for males and between 45 and 100 kg for females.
  3. No clinical laboratory values (Hematology, coagulation, biochemistry and urinalysis) at the discretion of the PI.
  4. Females of child bearing potential must use an acceptable, highly effective double and have a negative pregnancy test at Screening and Day-1.
  5. Documented evidence of surgical sterilization at least 6 months prior to screening for women or vasectomy at least 90 days prior to screening.
  6. Women not of child bearing potential must be menopausal for >/= 12 months.
  7. Males must not donate sperms for at least 90 days after PMG1015 administration.

Exclusion criteria

Exclusion Criteria:

  1. History or evidence of condition, including but not limited to any cardiovascular, gastrointestinal, endocrinologic, hematologic, psychiatric, renal disease, musculoskeletal, infectious, or neurological condition or any chronic medical condition and/or other major disease, as determined by the PI.
  2. A PR \< 40 or > 100 beats per minute, mean systolic blood pressure (SBP) > 140 mmHg, or mean diastolic blood pressure (DBP) > 95 mmHg .
  3. A mean interval using Fridericia's formula (QTcF) interval at Screening > 450 ms in males and > 470 ms in females. If the mean QTcF exceeds these limits, one additional triplicate will be performed.
  4. Any clinically significant abnormalities in rhythm, conduction, or morphology of the resting ECG and any abnormalities in the 12-lead ECG that, in the judgment of the PI, may interfere with the interpretation of QTc-interval changes, including abnormal ST-T wave morphology or left ventricular hypertrophy.
  5. (ALT), aspartate aminotransferase (AST), or creatinine > 1.5 × the (ULN) or total or lymphocyte counts > ULN.
  6. Participants with a positive toxicology screening panel or alcohol breath test on Screening/Day-1.
  7. Participants with a history of substance abuse or dependency or history of recreational IV drug use over the last 2 years.
  8. Plasma donation/Blood donation or significant blood loss within 60 days prior to the first IP administration.
  9. Use of any IP (including other mAb products) or investigational medical device within 30 days prior to Screening or 5 half-lives of the product (whichever is the longest) or participation in more than 4 investigational drug studies within 1 year prior to screening.
  10. Major surgery (general anesthetic) within 3 months or minor surgery (local anesthetic) within 1 month prior to IP administration, or planned surgery during the study period, which is determined by the PI to be clinically relevant.
  11. Fever or symptomatic bacterial or viral infection.
  12. Participants who have received or attenuated vaccines within 1 month before dosing.
  13. Participants with any active or history of malignancy within 5 years prior to enrolment.
  14. Use of any other prescription medications.
  15. History of anaphylaxis, allergic reactions to the of IP, asthma.
  16. Positive blood screen for HIV1/2 antibody, surface antigen, virus, or syphilis at screening.
  17. Participants with an inability to tolerate venous access.
  18. Pregnant or lactating at Screening or planning to become pregnant (self or partner) at any time during the study, including the follow-up period.
  19. An employee of Pulmongene or Novotech (Australia) Pty Ltd.
  20. Participant is unwilling to abstain from alcohol beginning 48 hours prior to admission to the CRU and while resident at the CRU.
  21. Any other condition or finding that in the opinion of the PI or designee would put the participant or study conduct at risk.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Single Ascending Doses Cohort 1a

    Subjects will receive either Dose level 1 of PMG1015 or Placebo

    Drug: PMG1015 Dose 1 · Drug: Placebo

  • Experimental
    Single Ascending Doses Cohort 1b

    Subjects will receive either Dose level 2 of PMG1015 or Placebo

    Drug: PMG1015 Dose 2 · Drug: Placebo

  • Experimental
    Single Ascending Doses Cohort 1c

    Subjects will receive either Dose level 3 of PMG1015 or Placebo

    Drug: PMG1015 Dose 3 · Drug: Placebo

  • Experimental
    Single Ascending Doses Cohort 1d

    Subjects will receive either Dose level 4 of PMG1015 or Placebo

    Drug: PMG1015 Dose 4 · Drug: Placebo

  • Experimental
    Single Ascending Doses Cohort 1e

    Subjects will receive either Dose level 5 of PMG1015 or Placebo

    Drug: PMG1015 Dose 5 · Drug: Placebo

  • Experimental
    Single Ascending Doses Cohort 1f

    Subjects will receive either Dose level 6 of PMG1015 or Placebo

    Drug: PMG1015 Dose 6 · Drug: Placebo

  • Experimental
    Single Ascending Doses Cohort 1g

    Subjects will receive either Dose level 7 of PMG1015 or Placebo

    Drug: Placebo · Drug: PMG1015 Dose 7

Interventions

  • DrugPMG1015 Dose 1

    Dose level 1 of PMG1015

    Also known as: PMG1015

  • DrugPMG1015 Dose 2

    Dose level 2 of PMG1015

    Also known as: PMG1015

  • DrugPMG1015 Dose 3

    Dose level 3 of PMG1015

    Also known as: PMG1015

  • DrugPMG1015 Dose 4

    Dose level 4 of PMG1015

    Also known as: PMG1015

  • DrugPMG1015 Dose 5

    Dose level 5 of PMG1015

    Also known as: PMG1015

  • DrugPMG1015 Dose 6

    Dose level 6 of PMG1015

    Also known as: PMG1015

  • DrugPlacebo

    Placebo to match

  • DrugPMG1015 Dose 7

    Dose level 7 of PMG1015

    Also known as: PMG1015

06

What researchers measure

Primary outcomes

  1. The incidence of Treatment-emergent adverse events (TEAEs)

    An Adverse Event (AE) is any event, side-effect or any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs are AEs that occur following the start of treatment.

    Time frame: Day 1-Day 85

  2. The severity of Treatment-emergent adverse events (TEAEs)

    TEAEs are AEs that occur following the start of treatment.

    Time frame: Day 1-Day 85

  3. The incidence of Serious adverse events (SAEs)

    A serious adverse event (SAE) is defined as an AE occurring during any study phase and at any dose of IP (active or placebo) that results in death; is life threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; results in congenital anomaly/birth defect.

    Time frame: Day 1-Day 85

  4. The severity of Serious adverse events (SAEs)

    A serious adverse event (SAE) is defined as an AE occurring during any study phase and at any dose of IP (active or placebo) that results in death; is life threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; results in congenital anomaly/birth defect.

    Time frame: Day 1- Day 85

  5. Number of participants with abnormally clinical vital signs

    Vital signs include pulse rate (PR), blood pressure (BP), respiratory rate (RR) and tympanic temperature (T)

    Time frame: Day 1- Day 85

  6. Number of participants with abnormal clinically significant 12-lead electrocardiogram (ECG) parameters

    All ECG tracings will be reviewed by the PI or designee and assessed for clinical significance.

    Time frame: Day 1-Day 85.

  7. Number of participants with abnormal clinically significant clinical laboratory results

    Clinical laboratory test include hematology, coagulation, biochemistry, and urinalysis.

    Time frame: Day 1- Day 85

  8. MTD of PMG1015 in healthy participants

    Maximum tolerated dose of PMG1015 in healthy participants

    Time frame: Day 1- Day 85

  9. Number of patients with abnormal clinically significant results from physical examination

    Complete physical examination include, general appearance, head, eyes, ears, nose, throat, dentition, thyroid, chest (heart, lungs), abdomen, skin, neurological, extremities, back, neck, musculoskeletal, and lymph nodes.

    Time frame: Day 1-Day 85

Secondary outcomes

  1. Area under the serum-concentration time curve (AUC) from time zero (from the start of infusion time) to the last time point with measurable analyte concentration (AUC0-t)

    Area under the plasma concentration versus time curve (AUC) from time 0 to time of last quantifiable concentration

    Time frame: Day 1-Day 85.

  2. AUC from time zero to infinity (AUC0-∞)

    Area under the plasma concentration versus time curve (AUC) from time 0 (from the start of infusion) extrapolated to infinity

    Time frame: Day 1-Day 85.

  3. To determine %AUCexp

    The percentage of the AUC that has been extrapolated beyond the last observed data point

    Time frame: Day 1-Day 85.

  4. To determine Cmax

    Maximum observed serum PMG1015 concentration

    Time frame: Day 1-Day 85.

  5. To determine Tmax, derived from serum concentration of each dose of PMG1015

    Time to maximum observed concentration

    Time frame: Day 1-Day 85.

  6. To determine t1/2

    Terminal elimination half life summarized by dosing regimen

    Time frame: Day 1-Day 85.

  7. Apparent total body clearance (CL)

    CL is the measure of the rate at which a drug is metabolized or eliminated by normal biological processes

    Time frame: Day 1-Day 85.

  8. Apparent volume of distribution during the terminal phase (Vz)

    Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.

    Time frame: Day 1-Day 85.

  9. Apparent terminal elimination rate constant (λz or kel)

    λz is calculated using log-linear regression of the terminal portions of the plasma concentrations versus time curves.

    Time frame: Day 1-Day 85.

  10. Levels of ADA

    Anti-drug antibody levels in blood

    Time frame: Day 1-Day 85

07

Study locations

1 site
  • Q-Pharm Pty Ltd, Clive Berghofer Cancer Research Centre
    Herston, Queensland 4006, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Aug 2022, 10 months.

Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 10 months is close to that.

Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2021
First posted
Aug 26, 2021
StartActual
Oct 14, 2021
Primary completionActual
Aug 18, 2022
CompletionActual
Aug 18, 2022
Last update
Jan 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05022771
Lead sponsor
Pulmongene Ltd.
Responsible party
Sponsor
First posted
Aug 26, 2021
Start date
Oct 14, 2021
Primary completion
Aug 18, 2022
Completion
Aug 18, 2022
Last update
Jan 31, 2023

Study contacts

Richard Friend
principal investigator · Nucleus Network

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion